Correction: Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP/PS1 mice

Haobin Cai; Yijie Wang; Jiayang He; Tiantian Cai; Jun Wu; Jiansong Fang; Rong Zhang; Zhouke Guo; Li Guan; Qinkai Zhan; Li Lin; Yao Xiao; Huafeng Pan; Qi Wang

doi:10.18632/oncotarget.22813

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP/PS1 mice

PDF | How to cite

Oncotarget. 2018; 9:25750-25750. https://doi.org/10.18632/oncotarget.22813

Metrics: PDF 1547 views | ?

Haobin Cai^2,1, Yijie Wang¹, Jiayang He¹, Tiantian Cai¹, Jun Wu¹, Jiansong Fang¹, Rong Zhang¹, Zhouke Guo², Li Guan¹, Qinkai Zhan¹, Li Lin³, Yao Xiao⁴, Huafeng Pan¹ and Qi Wang¹

¹Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
²Department of Neurology & Psychology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518033, China
³Guangzhou University of Chinese Medicine, Guangzhou 510405, China
⁴Guangzhou Medical University, Guangzhou 510182, China

Published: May 22, 2018

This article has been corrected: The correct 2nd affiliation and author name is given below:

Haobin Cai^2,1

²Department of Neurology & Psychology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518033, China

Original article: Oncotarget. 2017; 8:92621-92634. DOI: https://doi.org/10.18632/oncotarget.21515.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22813

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP/PS1 mice